Pfizer Inc. has named company veteran Albert Bourla as group president of its Vaccines, Oncology and Consumer Healthcare business.


Pfizer, Albert Bourla, Vaccines, Oncology and Consumer Healthcare business, Ian Read, Suan Silbermann, Global Vaccines business, Amy Schulman, Doug Lankler, Rady Johnson










































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Pfizer appoints new head of vaccines, oncology, consumer health unit

December 17th, 2013

NEW YORK – Pfizer Inc. has named company veteran Albert Bourla as group president of its Vaccines, Oncology and Consumer Healthcare business.

The pharmaceutical maker said Tuesday that Bourla is slated to take over the role on Jan. 1.

"Albert has 20 years of experience at Pfizer and has held senior global positions across a range of markets and disciplines within the company," stated Ian Read, Pfizer chairman and chief executive officer. "He has a track record for delivering solid business results and most recently has been responsible for building a strong post-patent business."

In addition, Pfizer has appointed Susan Silbermann as president and general manager of its Global Vaccines business effective Jan. 1.

"For the past year and a half, Susan has led the vaccines portfolio within the Specialty Care business. Her experience in key global markets that represent potential growth opportunities will greatly benefit the vaccines business," Read commented.

The appointments come with Pfizer's announcement Tuesday that Amy Schulman is slated to leave the company. Pfizer said that, as a result, Schulman will not be assuming the role of group president of Vaccines, Oncology and Consumer Healthcare and is stepping down from the company's executive leadership team, including as general counsel and business unit Lead for the Consumer Healthcare business. She will remain at the company for a transition period, according to Pfizer.

"We thank Amy for the past five years of hard work and many contributions, and we wish her well in her future endeavors," the company stated.

Doug Lankler, who was set become General Counsel on Jan.1, and Rady Johnson, who was to become Chief Compliance and Risk Officer on Jan. 1, both assume their new positions immediately.

On that date, Pfizer plans to begin operating with three commercial businesses: the Global Innovative Pharmaceutical business, led by Geno Germano; the Global Established Pharmaceutical business, led by John Young; and the Vaccines, Oncology and Consumer Healthcare business, led by Albert Bourla.

More Supplier News Breaks >>
Advertisement